Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments-Reference-Cited by-同舟云学术

Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments

Published:2018-02-05 Issue:3 Volume:7 Page:175-185
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Calvier Elisa A. M.¹,Krekels Elke H. J.¹,Yu Huixin¹,Välitalo Pyry A. J.¹,Johnson Trevor N.²,Rostami-Hodjegan Amin²³,Tibboel Dick⁴,van der Graaf Piet H.⁵,Danhof Meindert¹,Knibbe Catherijne A. J.¹⁶

Affiliation:

1. Division Systems Biomedicine and Pharmacology; Leiden Academic Centre for Drug Research (LACDR), Leiden University; Leiden The Netherlands

2. Simcyp Limited; Sheffield United Kingdom

3. Manchester Pharmacy School, University of Manchester; Manchester United Kingdom

4. Intensive Care and Department of Pediatric Surgery; Erasmus University Medical Center - Sophia Children's Hospital; Rotterdam The Netherlands

5. QSP, Certara; Canterbury United Kingdom

6. Department of Clinical Pharmacy; St. Antonius Hospital; Nieuwegein The Netherlands

Funder

Innovational Research Incentives Scheme

Netherlands Organisation for Scientific Research

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Reference36 articles.

1. The role of modeling and simulation in development and registration of medicinal products: output from the EFPIA/EMA Modeling and Simulation Workshop;Manolis;CPT Pharmacometrics Syst. Pharmacol.,2013

2. Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling;Brussee;Expert Rev. Clin. Pharmacol.,2016

3. US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER) https://www.fda.gov/ohrms/dockets/ac/03/briefing/3927B1_04_GFI-Pharmacokinetic Guidance.pdf 1998

4. Drug development for pediatric populations: regulatory aspects;Zisowsky;Pharmaceutics,2010

5. Physiologically based pharmacokinetics (PBPK);Espié;Drug Metab. Rev.,2009

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model-informed drug development in pediatric, pregnancy and geriatric drug development: States of the art and future;Advanced Drug Delivery Reviews;2024-08

2. Impact of Obesity on Hepatic Drug Clearance: What are the Influential Variables?;The AAPS Journal;2024-05-09

3. Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes;Expert Opinion on Drug Metabolism & Toxicology;2022-10-03

4. An Update on the Use of Allometric and Other Scaling Methods to Scale Drug Clearance in Children: Towards Decision Tables;Expert Opinion on Drug Metabolism & Toxicology;2022-02-01

5. Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development;AAPS PharmSciTech;2021-07-26